TXR-1002 / Aria Pharma - LARVOL DELTA

Aria Pharmaceuticals Presents Positive In Vivo Data on Lead Idiopathic Pulmonary Fibrosis Treatment Candidate (PRNewswire) - "Aria Pharmaceuticals...announced that its lead candidate for idiopathic pulmonary fibrosis (IPF), TXR-1002, demonstrated significant efficacy in new preclinical research. TXR-1002 represents a completely new novel mechanism of action for the potential treatment of IPF. Data was presented at the 6th Annual Antifibrotic Drug Development Summit on November 10 in Boston....'We continue to see promising data for our IPF candidate TXR-1002, validating our efforts to advance this program toward IND-enabling studies.'...'This is our third robust preclinical study for TXR-1002 that showed positive results and by utilizing a more advanced rat model. We are confident in the promise of this treatment as a viable candidate for clinical research.'"

Preclinical • Idiopathic Pulmonary Fibrosis

Aria Pharmaceuticals Advances Pipeline with Six Provisional US Patents Filed Across Three Diseases (PRNewswire) - "Aria Pharmaceuticals...announced that the company has successfully filed a total of six provisional patents with the United States Patent and Trademark Office (USPTO) for lead candidates in its lupus, idiopathic pulmonary fibrosis (IPF), and chronic kidney disease (CKD) research programs....TXR-1002, an investigational treatment for idiopathic pulmonary fibrosis (IPF): Inhibits myofibroblast proliferation, collagen, TGF-b, fibrosis, and inflammation."

Patent • Idiopathic Pulmonary Fibrosis

Aria Pharmaceuticals Presents Positive In Vivo Data Showing Two Novel Treatment Candidates Demonstrated Positive Efficacy and Tolerability in Idiopathic Pulmonary Fibrosis Compared to Standard of Care (PRNewswire) - "Aria Pharmaceuticals...today announced that two novel candidates for the potential treatment of idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies....'So far, the data for both novel candidates are very promising, and we're thrilled to present our findings at this year's IPF Summit'....In vivo efficacy with TXR-1002 and TXR-1007 was evaluated using a bleomycin-induced IPF mouse model. Data shows that both TXR-1002 and TXR-1007 decrease fibrosis and significantly decrease lung collagen staining..."

Preclinical • Idiopathic Pulmonary Fibrosis • Respiratory Diseases